How growth hormone may be linked to cancer: concerns and perspective

References

• Drazen JM. Inappropriate advertising of dietary supplements. N. Engl. J. Med.348, 777–778 (2003).
   PubMed Web of Science ®Google Scholar
• Michels KB, Xue F. Role of birthweight in the etiology of breast cancer. Int. J. Cancer119, 2007–2025 (2006).
   PubMed Web of Science ®Google Scholar
• Gunnell D, Okasha M, Smith GD, Oliver SE, Sandhu J, Holly JM. Height, leg length, and cancer risk: a systematic review. Epidemiol. Rev.23, 313–342 (2001).
   PubMed Web of Science ®Google Scholar
• Maison P, Balkau B, Simon D, Chanson P, Rosselin G, Eschwege E. Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ316, 1132–1133 (1998).
   Web of Science ®Google Scholar
• Borofsky ND, Vogelman JH, Krajcik RA, Orentreich N. Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin. Chem.48, 2248–2251 (2002).
   Google Scholar
• Gapstur SM, Kopp P, Chiu BC, Gann PH, Colangelo LA, Liu K. Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in black and white men: the CARDIA Male Hormone Study. Cancer Epidemiol. Biomarkers Prev.13, 2208–2216 (2004).
   Google Scholar
• Aimaretti G, Corneli G, Rovere S et al. Insulin-like growth factor I levels and the diagnosis of adult growth hormone deficiency. Horm. Res.62(Suppl. 1), 26–33 (2004).
   Google Scholar
• Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet363, 1346–1353 (2004).
   PubMed Web of Science ®Google Scholar
• Pollak MN SE, Schernhammer ES, Hankinson SE. A comprehensive review of the epidemiological evidence linking IGF-I with cancer, potential mechanisms and clinical implications. Nat. Rev. Cancer4, 505–518 (2004).
   PubMed Web of Science ®Google Scholar
• Fletcher O, Gibson L, Johnson N et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer. A systematic review. Cancer Epidemiol. Biomarkers Prev.14, 2–19 (2005).
   PubMed Web of Science ®Google Scholar
• Crown AL, Cottle K, Lightman SL et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin. Endocrinol. (Oxford)56, 723–733 (2002).
   Google Scholar
• Cotterill AM, Holly JM, Davies SC, Coulson VJ, Price PA, Wass JA. The insulin-like growth factors and their binding proteins in a case of non-islet-cell tumour-associated hypoglycaemia. J. Endocrinol.131, 303–311 (1991).
   Google Scholar
• Rinaldi S, Peeters PH, Berrino F et al. IGF-I, IGFBP-3 and breast cancer risk in women. The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer13, 593–605 (2006).
   PubMed Web of Science ®Google Scholar
• Rollinson DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int. J. Cancer48, 2248–2251 (2006).
   Google Scholar
• Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology83, 154–160 (2006).
   PubMed Web of Science ®Google Scholar
• Jenkins PJ. Cancers associated with acromegaly. Neuroendocrinology83, 218–223 (2006).
   Google Scholar
• Swerdlow AJ. Does growth hormone therapy increase the risk of cancer? Nat. Clin. Pract. Endocrinol. Metab.2, 530–531 (2006).
   Google Scholar
• Dunn SE, Kari FW, French J et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res.57, 4667–4672 (1997).
   PubMed Web of Science ®Google Scholar
• Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu. Rev. Med.54, 131–152 (2003).
   PubMed Web of Science ®Google Scholar
• Rudd MF, Webb EL, Matakidou A et al. Variants in the GH–IGF axis confer susceptibility to lung cancer. Genome Res.16, 693–701 (2006).
   PubMed Web of Science ®Google Scholar
• Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR. Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J. Natl Cancer Inst.94, 454–460 (2002).
   PubMedGoogle Scholar
• Wong HL, Delellis K, Probst-Hensch N et al. A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore Chinese. Cancer Epidemiol. Biomarkers Prev.14, 144–151 (2005).
   Google Scholar
• Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev.14, 1204–1211 (2005).
   PubMedGoogle Scholar
• Zecevic M, Amos CI, Gu X et al. IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. J. Natl Cancer Inst.98, 139–143 (2006).
   Google Scholar
• Le Marchand L, Kolonel LN, Henderson BE, Wilkens LR. Association of an exon 1 polymorphism in the IGFBP3 gene with circulating IGFBP-3 levels and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev.14, 1319–1321 (2005).
   PubMed Web of Science ®Google Scholar
• Slattery ML, Curtin K, Wolff R et al. PPARγ and colon and rectal cancer. associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control17, 239–249 (2006).
   Google Scholar
• Cheng I, Stram DO, Penney KL et al. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J. Natl Cancer Inst.98, 123–134 (2006).
   Google Scholar
• Johansson M, McKay JD, Stattin P et al. Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. Int. J. Cancer120, 539–542 (2007).
   Google Scholar
• Wang L, Habuchi T, Tsuchiya N et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res.63, 4407–4411 (2003).
   Google Scholar
• Chen C, Freeman R, Voigt LF, Fitzpatrick A, Plymate SR, Weiss NS. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol. Biomarkers Prev.15, 2461–2466 (2006).
   Google Scholar
• McKay JD, Kaaks R, Johansson M et al. Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev.16, 169–173 (2007).
   Google Scholar
• Yu H, Li BD, Smith M, Shi R, Berkel HJ, Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res. Treat.70, 117–122 (2001).
   Google Scholar
• Figer A, Karasik YP, Baruch RG et al. Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women. Isr. Med. Assoc. J.4, 759–762 (2002).
   Google Scholar
• Wen W, Gao YT, Shu XO et al. Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women. Int. J. Cancer113, 307–311 (2005).
   Google Scholar
• Cleveland RJ, Gammon MD, Edmiston SN et al. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis27, 758–765 (2006).
   Google Scholar
• Henningson M, Bageman E, Sandberg T, Borg A, Olsson H, Jernstrom H. Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families. Fam. Cancer2007.
   Google Scholar
• Al-Zahrani A, Sandhu MS, Luben RN et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum. Mol. Genet.15, 1–10 (2006).
   PubMed Web of Science ®Google Scholar
• Tamimi RM, Cox DG, Kraft P et al. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density. a cross-sectional study. Breast Cancer Res.9, R18 (2007).
   Google Scholar
• Jernstrom H, Sandberg T, Bageman E, Borg A, Olsson H. Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Int. J. Gynecol. Cancer16(Suppl. 2), 497 (2006).
   Google Scholar
• Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol. Biomarkers Prev.13, 573–582 (2004).
   PubMed Web of Science ®Google Scholar
• Duan QH, Wang ZG, Zhu GB, Lu ZX, Shi LY, Nie SF. Study on the relations between serum insulin-like growth factor-1, insulin-like growth factor binding protein-3 and colorectal cancer: a meta-analysis. Zhonghua Liu Xing Bing Xue Za Zhi26, 132–134 (2005).
   Google Scholar
• Morris JK, George LM, Wu T, Wald NJ. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br. J. Cancer95, 112–117 (2006).
   Google Scholar
• Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int. J. Cancer111, 418–423 (2004).
   PubMed Web of Science ®Google Scholar
• Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K. Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int. J. Cancer111, 293–297 (2004).
   PubMed Web of Science ®Google Scholar
• Malone KE, Daling JR, Doody DR et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black american women ages 35 to 64 years. Cancer Res.66, 8297–8308 (2006).
   PubMed Web of Science ®Google Scholar
• Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm. IGF Res.16, 277–289 (2006).
   PubMed Web of Science ®Google Scholar
• Pollak MN. Insulin-like growth factors and neoplasia. Novartis Found. Symp.262, 84–107 (2004).
   PubMedGoogle Scholar
• Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev.28, 20–47 (2007).
   PubMed Web of Science ®Google Scholar
• Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev.16, 407–420 (2005).
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature411, 342–348 (2001).
   PubMed Web of Science ®Google Scholar
• Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer107, 873–877 (2003).
   PubMed Web of Science ®Google Scholar
• Granata R, Trovato L, Lupia E et al. Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J. Thromb. Haemost.5, 835–845 (2007).
   PubMed Web of Science ®Google Scholar
• Lofqvist C, Chen J, Connor KM et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc. Natl Acad. Sci. USA104, 10589–10594 (2007).
   PubMed Web of Science ®Google Scholar
• Chang KH, Chan-Ling T, McFarland EL et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc. Natl Acad. Sci. USA104, 10595–10600 (2007).
   PubMed Web of Science ®Google Scholar
• Schoen RE, Weissfeld JL, Kuller LH et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology129, 464–475 (2005).
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Ferone D et al. Prostatic hyperplasia. An unknown feature of acromegaly. J. Clin. Endocrinol. Metab.83, 775–779 (1998).
   PubMed Web of Science ®Google Scholar
• Nam RK, Trachtenberg J, Jewett MA et al. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia. A clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev.14, 1270–1273 (2005).
   PubMed Web of Science ®Google Scholar
• Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res.60, 3744–3748 (2000).
   PubMed Web of Science ®Google Scholar
• dos Santos Silva I, Johnson N, De Stavola B et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol. Biomarkers Prev.15, 449–455 (2006).
   Google Scholar
• Green DR, Evan GI. A matter of life and death. Cancer Cell1, 19–30 (2002).
   PubMed Web of Science ®Google Scholar
• Vineis P. Cancer as an evolutionary process at the cell level: an epidemiological perspective. Carcinogenesis24, 1–6 (2003).
   PubMed Web of Science ®Google Scholar
• Jonason AS, Kunala S, Price GJ et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc. Natl Acad. Sci. USA93, 14025–14029 (1996).
   PubMed Web of Science ®Google Scholar
• Peto J. Cancer epidemiology in the last century and the next decade. Nature411, 390–395 (2001).
   PubMed Web of Science ®Google Scholar
• Maskarinec G, Takata Y, Chen Z et al. IGF-I and mammographic density in four geographic locations. A pooled analysis. Int. J. Cancer121, 1786–1792 (2007).
   Google Scholar
• Michels KB, Willett WC. Breast cancer – early life matters. N. Engl. J. Med.351, 1679–1681 (2004).
   Google Scholar
• Ginestier C, Wicha MS. Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res.9, 109 (2007).
   PubMedGoogle Scholar
• King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science302, 643–646 (2003).
   PubMed Web of Science ®Google Scholar
• Tryggvadottir L, Sigvaldason H, Olafsdottir GH et al. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920–2000. J. Natl Cancer Inst.98, 116–122 (2006).
   Google Scholar
• Nkondjock A, Robidoux A, Paredes Y, Narod SA, Ghadirian P. Diet, lifestyle and BRCA-related breast cancer risk among French–Canadians. Breast Cancer Res. Treat.98, 285–294 (2006).
   Google Scholar
• Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J. Clin. Endocrinol. Metab.85, 3653–3660 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J. Clin. Endocrinol. Metab.92, 2480–2486 (2007).
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85, a cohort study. Lancet360, 273–277 (2002).
   PubMed Web of Science ®Google Scholar
• Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case–control study. Circulation106, 939–944 (2002).
   PubMed Web of Science ®Google Scholar
• Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet359, 1740–1745 (2002).
   PubMed Web of Science ®Google Scholar
• Kalmijn S, Janssen JA, Pols HA, Lamberts SW, Breteler MM. A prospective study on circulating insulin-like growth factor I (IGF-I), IGF-binding proteins, and cognitive function in the elderly. J. Clin. Endocrinol. Metab.85, 4551–4555 (2000).
   PubMed Web of Science ®Google Scholar
• Boonen S, Lesaffre E, Dequeker J et al. Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years. potential implications for the prevention of age-related bone loss. J. Am. Geriatr. Soc.44, 1301–1306 (1996).
   Google Scholar
• Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N. Engl. J. Med.351, 2694–2703 (2004).
   PubMed Web of Science ®Google Scholar
• Twombly R. Cancer surpasses heart disease as leading cause of death for all but the very elderly. J. Natl Cancer Inst.97, 330–331 (2005).
   PubMed Web of Science ®Google Scholar
• LeRoith D, Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell5, 201–202 (2004).
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther.6, 1–12 (2007).
   PubMed Web of Science ®Google Scholar
• Carro E, Trejo JL, Gerber A et al. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol. Aging27, 1250–1257 (2006).
   PubMedGoogle Scholar
• Gunnell D, Oliver SE, Peters TJ et al. Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br. J. Cancer88, 1682–1686 (2003).
   PubMed Web of Science ®Google Scholar
• Mucci LA, Tamimi R, Lagiou P et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int.87, 814–820 (2001).
   PubMed Web of Science ®Google Scholar